Clinical PK

Formulas 1

General PK

1-Compartment Model

Vancomycin 1, 2, 3, 4

Peak: 20-40 mg/L

Trough: 10-15 mg/L (minor infections) or 15-20 mg/L (serious infections or lung penetration)

Loading Dose: 25-30 mg/kg (Wt)

NTE 15 mg/min

k ≈ 0.00083 × CrCl + 0.0044

Vd ≈ 0.4-1 L/kg, usually 0.6-0.7 L/kg

for appropriate effect

to prevent toxicity

Initial Vanc Dosing Calculator

Level-Based Vanc Dosing Calculator

Aminoglycosides 1, 5

See also: Stanford Aminoglycoside Dosing Guidelines

k ≈ 0.0024 × CrCl + 0.01

Vd ≈ 0.26 L/kg × Wt

Vd may be closer to 0.3-0.35 L/kg in critically ill pts due to fluid overload

Use ABW if Wt/IBW > 130%

Traditional Dosing

Gentamicin / Tobramycin Target Levels 1, 6

Infection Target Peak (mcg/mL) Target Trough (mcg/mL)
General 4-10 le; 1
UTI < 5 ≤ 1
Bacteremia > 5 ≤ 1
Pneumonia > 6 ≤ 1
Endocarditis from P. aeruginosa > 12 ≤ 1

Amikacin Target Levels 1, 6

Infection Target Peak (mcg/mL) Target Trough (mcg/mL)
General 15-30 4-10
UTI > 15 4-10
Bacteremia > 20 4-10
Pneumonia /Serious Infections > 24 4-10

Target Cpk / MIC > 10 for efficacy Draw levels 1hr after infusion ends Consider target troughs of ≤ 1.5-2 (tob/gent) or ≤ 10 (amikacin) for life-threatening infections. Look up specific trough/peak targets for given infection site.

Initial Aminoglycoside Dosing Calculator

Extended-Interval Dosing

  1. Load with 7 mg/kg (15 mg/kg Amikacin)

  2. Determine initial dosing frequency from table below

  3. Draw level at 6-14hr after 1st or 2nd dose

  4. Plot level on Hartford Nomogram (divide level by 2 for Amikacin)

    • If doses other than those above are used, multiplying the level by (expected)/(given) dose can help adjust properly for the nomogram, although this has less evidence
  5. Adjust interval per nomogram

  6. If borderline, go with longer interval

Hartford Nomogram

Hartford Nomogram

Initial Aminoglycoside Interval

CrCl Interval
≥ 60 Q24H
40-59 Q36H
20-39 Q48H
< 20 Monitor Serial Conc. & Admin when < 1 mcg/mL

References

  1. DiPiro JT, ed. Pharmacotherapy: A Pathophysiologic Approach. Tenth edition. New York: McGraw-Hill Education; 2017.  2 3 4 5

  2. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. American Journal of Health-System Pharmacy. 2009;66(1):82-98. doi:10.2146/ajhp080434 

  3. Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrobial Agents and Chemotherapy. 1984;25(4):433-437. doi:10.1128/AAC.25.4.433 

  4. Deryke CA, Alexander DP. Optimizing Vancomycin Dosing through Pharmacodynamic Assessment Targeting Area under the Concentration-Time Curve/Minimum Inhibitory Concentration. Hospital Pharmacy. 2009;44(9):751-765. doi:10.1310/hpj4409-751 

  5. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrobial Agents and Chemotherapy. 1995;39(3):650-655. doi:10.1128/AAC.39.3.650 

  6. Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: http://online.lexi.com 2

Author: Corbin Cox
Created: 2018-12-03
Last Updated: 2018-12-03